AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Mindmedicinelaw

Published November 14, 2026 · Updated November 15, 2026

Safety and Implementation of Ketamine, Psilocybin, and rTMS - The Psychedelic Journal

Read the full story at Mindmedicinelaw

A major 2026 review synthesizes evidence on ketamine , psilocybin, and rTMS for treatment-resistant depression, outlining efficacy, safety gaps,.

Post on X

Share this story

Surfaced by this Google Alert

Ketamine